No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA).

Cai, Bin; Simon, James; Villa, Paola; Biglia, Nicoletta; Panay, Nicholas; Djumaeva, Stora; Particco, Martire; Kanakamedala, Hemanth; Altomare, Corrado

doi:10.1016/j.maturitas.2020.06.021

Record: found
Abstract: found
Article: not found

No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA).

Author(s): Bin Cai, James Simon, Paola Villa, Nicoletta Biglia, Nicholas Panay, Stora Djumaeva, Martire Particco, Hemanth Kanakamedala, Corrado Altomare

Publication date: 2020-12-01

Journal: Maturitas

Publisher: Elsevier BV

Keywords: Vulvovaginal atrophy (VVA), Ospemifene, Breast cancer recurrence, Breast cancer incidence

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To estimate the incidence and recurrence of breast cancer (BC) in patients with vulvovaginal atrophy (VVA) treated with ospemifene and matched untreated VVA patients using real-world data.